The Effects of Probiotic Formulation Pretreatment (<i>Lactobacillus helveticus</i> R0052 and <i>Bifidobacterium longum</i> R0175) on a Lipopolysaccharide Rat Model

Mohammadi, Ghazaleh; Dargahi, Leila; Peymani, Amir; Mirzanejad, Yazdan; Alizadeh, Safar Ali; Naserpour, Taghi; Nassiri‐Asl, Marjan

doi:10.1080/07315724.2018.1487346

Cited by 55 publications

(29 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the literature, many of the 51 genomes of L. helveticus deposited possess proven probiotic capability, namely, R0052 (Mohammadi et al, 2018), KLDS1.8701 (Li et al, 2017), CAUH18 (Yang et al, 2016), MB2-1 (Li et al, 2015a), MTCC5 463 (Senan et al, 2015a), H9 (Chen et al, 2015), M92 (Beganović et al, 2013), and D75 and D76 (Roshchina et al, 2018). Specifically, R0052 is characterized by the production of mucus-binding proteins and surface-layer proteins; CAUH18, by EPS formation and cell aggregation properties; and M92, H9, D75, and D76, by their proteolytic activity and bacteriocin production.…”

Section: Introductionmentioning

confidence: 99%

Genomic Comparison of Lactobacillus helveticus Strains Highlights Probiotic Potential

et al. 2019

View full text Add to dashboard Cite

Lactobacillus helveticus belongs to the large group of lactic acid bacteria (LAB), which are the major players in the fermentation of a wide range of foods. LAB are also present in the human gut, which has often been exploited as a reservoir of potential novel probiotic strains, but several parameters need to be assessed before establishing their safety and potential use for human consumption. In the present study, six L. helveticus strains isolated from natural whey cultures were analyzed for their phenotype and genotype in exopolysaccharide (EPS) production, low pH and bile salt tolerance, bile salt hydrolase (BSH) activity, and antibiotic resistance profile. In addition, a comparative genomic investigation was performed between the six newly sequenced strains and the 51 publicly available genomes of L. helveticus to define the pangenome structure. The results indicate that the newly sequenced strain UC1267 and the deposited strain DSM 20075 can be considered good candidates for gut-adapted strains due to their ability to survive in the presence of 0.2% glycocholic acid (GCA) and 1% taurocholic and taurodeoxycholic acid (TDCA). Moreover, these strains had the highest bile salt deconjugation activity among the tested L. helveticus strains. Considering the safety profile, none of these strains presented antibiotic resistance phenotypically and/or at the genome level. The pangenome analysis revealed genes specific to the new isolates, such as enzymes related to folate biosynthesis in strains UC1266 and UC1267 and an integrated phage in strain UC1035. Finally, the presence of maltose-degrading enzymes and multiple copies of 6-phospho-β-glucosidase genes in our strains indicates the capability to metabolize sugars other than lactose, which is related solely to dairy niches.

show abstract

Section: Introductionmentioning

confidence: 99%

Genomic Comparison of Lactobacillus helveticus Strains Highlights Probiotic Potential

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A probiotic mixture containing Lactobacillus acidophilus, L. fermentum, Bifidobacterium lactis and B. longum administered for 8 weeks to Ab(1-42)-injected rats improved spatial memory and learning deficits and decreased oxidative stress by modifying microbiota [159]. Manipulation of the gut microbiota with a combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 significantly decreased serum and hippocampus levels of pro-inflammatory cytokines, alleviated hippocampal apoptosis and attenuated the detrimental effect of LPS on memory through BDNF protein expression in LPSinduced rats [160,161]. Short-term administration of Bifidobacterium breve strain A1 prevented cognitive decline in AD mice, with a reduction in the immune response and neuronal inflammation.…”

Section: Preclinical Studies In Animal Modelsmentioning

confidence: 94%

Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease

et al. 2020

View full text Add to dashboard Cite

The gut microbiota coevolves with its host, and numerous factors like diet, lifestyle, drug intake and geographical location continuously modify its composition, deeply influencing host health. Recent studies demonstrated that gut dysbiosis can alter normal brain function through the so-called gut-brain axis, a bidirectional communication network between the central nervous system and the gastrointestinal tract, thus playing a key role in the pathogenesis of neurodegenerative disorders, such as Alzheimer's disease (AD). In this perspective, in the constant search for novel treatments in AD, the rational modulation of gut microbiota composition could represent a promising approach to prevent or delay AD onset or to counteract its progression. Preclinical and human studies on microbiota modulation through oral bacteriotherapy and faecal transplantation showed antiinflammatory and antioxidant effects, upregulation of plasma concentration of neuroprotective hormones, restoration of impaired proteolytic pathways, amelioration of energy homeostasis with consequent decrease of AD molecular hallmarks and improvement of behavioural and cognitive performances. In this review, we dissect the role of gut microbiota in AD and highlight recent advances in the development of new multitarget strategies for microbiota modulation to be used as possible preventative and therapeutic approaches in AD.

show abstract

“…infantis E41 and B. breve M2CF22M7 were shown to have an antidepressant effect in mice [57]. Importantly, probiotic pretreatment (L. helveticus R0052 + B. longum R0175) significantly alleviated hippocampal apoptosis induced by lipopolysaccharide in rats, suggesting that this probiotic could play a role in some neurodegenerative conditions [58,59]. Furthermore, not only stress-induced anxiety or depressive-like behaviours, but also cognitive deficits along with the reduced level of brain-derived neurotropic factor (BDNF) were alleviated by L. plantarum WLPL04 [60].…”

Section: Probiotics In Experimental Studiesmentioning

confidence: 99%

Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Gawlik-Kotelnicka

Strzelecki

2021

Pharmaceuticals

View full text Add to dashboard Cite

Depression and metabolic diseases often coexist, having several features in common, e.g., chronic low-grade inflammation and intestinal dysbiosis. Different microbiota interventions have been proposed to be used as a treatment for these disorders. In the paper, we review the efficacy of probiotics in depressive disorders, obesity, metabolic syndrome and its liver equivalent based on the published experimental studies, clinical trials and meta-analyses. Probiotics seem to be effective in reducing depressive symptoms when administered in addition to antidepressants. Additionally, probiotics intake may ameliorate some of the clinical components of metabolic diseases. However, standardized methodology regarding probiotics use in clinical trials has not been established yet. In this narrative review, we discuss current knowledge on the recently used methodology with its strengths and limitations and propose criteria that may be implemented to create a new study of the effectiveness of probiotics in depressive disorders comorbid with metabolic abnormalities. We put across our choice on type of study population, probiotics genus, strains, dosages and formulations, intervention period, as well as primary and secondary outcome measures.

show abstract

The Effects of Probiotic Formulation Pretreatment (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) on a Lipopolysaccharide Rat Model

Cited by 55 publications

References 81 publications

Genomic Comparison of Lactobacillus helveticus Strains Highlights Probiotic Potential

Genomic Comparison of Lactobacillus helveticus Strains Highlights Probiotic Potential

Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease

Probiotics as a Treatment for “Metabolic Depression”? A Rationale for Future Studies

Contact Info

Product

Resources

About